Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814912 | 0.88 | SLC18A3 (0.39) | OPRM1OPRL1SLC18A3L3MBTL3L3MBTL1 | |
| SCHEMBL2116420 | 0.87 | CHRM1 (0.33) | KDM4EALDH1A1KCNH2HRH3L3MBTL3 | |
| SCHEMBL2115687 | 0.87 | HRH3 (0.35) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL2116316 | 0.87 | KDM4E (0.47) | CYP2D6CYP2C19KDM4EALDH1A1ALOX15 | |
| SCHEMBL2114982 | 0.87 | LMNA (0.32) | KDM4EALDH1A1KCNH2HRH3OPRM1 | |
| SCHEMBL2118736 | 0.79 | POLB (0.37) | KDM4EALDH1A1KCNH2HRH3OPRM1 | |
| SCHEMBL5266154 | 0.79 | HRH3 (0.36) | CYP2D6CYP2C19HRH3OPRM1OPRL1 | |
| SCHEMBL2117147 | 0.79 | TSHR (0.42) | KCNH2HRH3OPRM1OPRL1SLC18A3 | |
| SCHEMBL2115182 | 0.79 | SLC18A3 (0.35) | HRH3OPRM1OPRL1SLC18A3L3MBTL3 | |
| SCHEMBL2114277 | 0.79 | TSHR (0.36) | KDM4EALDH1A1HRH3OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164854-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | PHARMACYCLICS LLC | 2015-06-18 | — | — | US | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | claimed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | claimed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | claimed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190184196-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10105552-B2 | Formulations of histone deacetylase inhibitor and uses thereof | PHARMACYCLICS LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170333731-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9492423-B2 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | PHARMACYCLICS LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164854-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | HDAC1, HDAC2, HDAC8 | CYP2D6 4194/4885CYP2C19 4143/4885KDM4E 463/4885 |
| US-20170333731-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | CYP2D6 4360/4885CYP2C19 3004/4885KDM4E 137/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | CYP2D6 2370/4885CYP2C19 2279/4885KDM4E 471/4885 |
| US-10105552-B2 | Formulations of histone deacetylase inhibitor and uses thereof | HDAC1, HDAC7, HDAC5 | CYP2D6 4360/4885CYP2C19 3004/4885KDM4E 137/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | CYP2D6 4233/4885CYP2C19 4082/4885KDM4E 561/4885 |
| US-20190184196-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | CYP2D6 4360/4885CYP2C19 3004/4885KDM4E 137/4885 |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | HDAC1, HDAC5, HDAC10 | CYP2D6 4603/4885CYP2C19 4532/4885KDM4E 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.